

Roche to present new data in blood cancers and solid tumours from its broad portfolio at ASCO 2023

Basel, 26 May 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will be presenting new data on six approved and investigational medicines across ten cancer types at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, held 2 – 6 June.

Highlights include new data spanning treatments for lymphoma and hepatocellular carcinoma (HCC):

Developing new treatment options for people with blood cancers

- Extended follow-up data for Columvi® (glofitamab) of almost two years (20 months) from the pivotal phase II NP30179 study, further investigating the potential of fixed-duration Columvi to provide durable responses in people with relapsed or refractory (R/R) large B-cell lymphoma (LBCL)
- Early data from the phase Ib NP40126 study of Columvi in combination with Polivy plus rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHP) in previously untreated DLBCL. These data support Roche's overall goal to develop combination treatments with Polivy® (polatuzumab vedotin) and its CD20xCD3 bispecific antibodies, Lunsumio® (mosunetuzumab) and Columvi (glofitamab) to optimise patient outcomes
- Subgroup analysis data from the phase III POLARIX trial of Polivy in combination with R-CHP in elderly patients with previously untreated DLBCL

Building on progress in treating liver cancer

- Analysis of patient-reported outcomes (PROs) from IMbrave050 in adjuvant hepatocellular carcinoma (HCC), including quality of life data. These data are intended to provide a more comprehensive evaluation of the patient experience during treatment with Tecentriq® (atezolizumab) plus Avastin® (bevacizumab). IMbrave050 is the first ever [phase III study](#) in the adjuvant HCC setting to show an improvement in recurrence-free survival
- Data from the randomised phase Ib study evaluating the investigational anti-TIGIT cancer immunotherapy tiragolumab in combination with Tecentriq plus Avastin compared with

Tecentriq and Avastin alone in unresectable HCC, which will inform further clinical development for this setting

Overview of key presentations featuring Roche medicines

| Medicine | Abstract title | Abstract number/presentation details |
|-----------------|---|---|
| Columvi | Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): results from a Phase Ib study [NP40126 study] | #7549 poster presentation Session: Hematologic Malignancies–Lymphoma and Chronic Lymphocytic Leukemia Monday 05 June, 2023 8:00-11:00 CT |
| | Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): extended follow-up and landmark analyses from a pivotal Phase II study [NP30179 study] | #7550 poster presentation Session: Hematologic Malignancies–Lymphoma and Chronic Lymphocytic Leukemia Monday 05 June, 2023 8:00-11:00 CT |
| Polivy | Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in the Phase 3 POLARIX study | #7518 poster discussion Session: Hematologic Malignancies–Lymphoma and Chronic Lymphocytic Leukemia Monday 05 June, 2023 08:00-11:00 CT (poster display) 13:15-14:45 CT (poster discussion) |
| Tiragolumab | Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic Hepatocellular Carcinoma (uHCC) | #4010 oral abstract session Session: Target or TIGIT in Hepatobiliary Cancer Sunday 04 June, 2023 16:30-18:00 CT |
| Tecentriq | Efficacy, safety and patient-reported outcomes (PROs) from the Phase III | #4002 oral abstract session Session: Gastrointestinal |

| | | |
|--|---|--|
| | IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | Cancer–Gastroesophageal, Pancreatic, and Hepatobiliary Friday 02 June, 2023 08:00-11:00 CT |
|--|---|--|

About Roche in Oncology

Roche has been working to transform cancer care for more than 50 years, bringing the first specifically designed anti-cancer chemotherapy drug, fluorouracil, to patients in 1962. Roche’s commitment to developing innovative medicines and diagnostics for cancers remains steadfast. The Roche Group’s portfolio of innovative cancer medicines includes: Alecensa®(alectinib); Avastin®(bevacizumab); Columvi®(glofitamab); Cotellic®(cobimetinib); Erivedge®(vismodegib); Gavreto®(pralsetinib); Gazyva®/Gazyvaro®(obinutuzumab); Herceptin®(trastuzumab); Kadcyra®(trastuzumab emtansine); Lunsumio®(mosunetuzumab); MabThera®/Rituxan®(rituximab); Perjeta®(pertuzumab); Polivy®(polatuzumab vedotin); Tarceva®(erlotinib); Rozlytrek®(entrectinib); Tecentriq®(atezolizumab); Venclexta®/Venclyxto®(venetoclax) in collaboration with AbbVie; Xeloda®(capecitabine); Zelboraf®(vemurafenib). Furthermore, the Roche Group has a robust investigational oncology pipeline focusing on new therapeutic targets and novel combination strategies. For more information on Roche’s approach to cancer, visit www.roche.com.

About Roche

Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognising our endeavour to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Roche Investor Relations

Dr. Bruno Eschli

Phone: +41 61 68-75284

e-mail: bruno.eschli@roche.com

Dr. Sabine Borngräber

Phone: +41 61 68-88027

e-mail: sabine.borngraeber@roche.com

Dr. Birgit Masjost

Phone: +41 61 68-84814

e-mail: birgit.masjost@roche.com

Dr. Gerard Tobin

Phone: +41 61 68-72942

e-mail: gerard.tobin@roche.com

Investor Relations North America

Loren Kalm

Phone: +1 650 225 3217

e-mail: kalm.loren@gene.com